share_log
Benzinga ·  Apr 25 08:07
Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment